Form 8-K - Current report:
SEC Accession No. 0001193125-25-268043
Filing Date
2025-11-06
Accepted
2025-11-06 07:03:49
Documents
12
Period of Report
2025-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amlx-20251106.htm   iXBRL 8-K 52003
2 EX-99.1 amlx-ex99_1.htm EX-99.1 209164
3 GRAPHIC img212534189_0.jpg GRAPHIC 631
  Complete submission text file 0001193125-25-268043.txt   384410

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20251106.xsd EX-101.SCH 27036
14 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20251106_htm.xml XML 4529
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 251456083
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)